Evaluation of intrapleural fibrinolytic therapy and dosing strategies used for complicated pleural effusions

IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pulmonary pharmacology & therapeutics Pub Date : 2022-10-01 DOI:10.1016/j.pupt.2022.102146
Laura Baumgartner , Eric Huang , Deborah Sherman
{"title":"Evaluation of intrapleural fibrinolytic therapy and dosing strategies used for complicated pleural effusions","authors":"Laura Baumgartner ,&nbsp;Eric Huang ,&nbsp;Deborah Sherman","doi":"10.1016/j.pupt.2022.102146","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Compare the use of Tissue Plasminogen Activator<span><span> (t-PA) and t-PA + Dornase (DNase) for the management of complicated </span>pleural effusions, and to determine if a dose-response relationship exists for t-PA.</span></p></div><div><h3>Methods</h3><p><span>Retrospective cohort study that examined all adult patients at a large academic medical center who received intrapleural t-PA or t-PA + DNase for the management of a complicated pleural effusions. Outcomes were success of therapy [defined as avoidance of secondary interventions (i.e. </span>VATSD or thoracotomy)], chest tube output pre- and post-administration, radiographic findings, t-PA dose and frequency, and bleeding complications.</p></div><div><h3>Results</h3><p>Thirty-five patients were enrolled: 25 received t-PA and 10 received t-PA + DNase. Successful pharmacologic treatment occurred in 88% of patients receiving t-PA and 100% of patients receiving t-PA + DNase (p = 0.54). In the t-PA group, chest tube output increased from 75 ml/12 h to 538 ml/12 h after administration of t-PA (p = 0.001), and from 103 ml/12 h to 502 ml/12 h (p = 0.001) in the t-PA + DNase group. Radiographic improvement occurred in 84% of t-PA patients and 90% of t-PA + DNase patients (p = 0.99). In the t-PA group, a successful response occurred in 92% of patients receiving a cumulative dose of ≤10 mg (n = 13) and 83% of patients receiving a cumulative dose of &gt;10 mg (n = 12), p = 0.43. Patients who received a single t-PA dose compared to those who received multiple doses also had similar success rates (p = 1). There was one instance of bleeding following drug administration.</p></div><div><h3>Conclusion</h3><p>Both t-PA and t-PA + DNase were highly effective for reducing a patient's need for surgical intervention. Higher cumulative doses or more frequency administrations did not appear to provide additional benefit.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary pharmacology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094553922000372","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

Compare the use of Tissue Plasminogen Activator (t-PA) and t-PA + Dornase (DNase) for the management of complicated pleural effusions, and to determine if a dose-response relationship exists for t-PA.

Methods

Retrospective cohort study that examined all adult patients at a large academic medical center who received intrapleural t-PA or t-PA + DNase for the management of a complicated pleural effusions. Outcomes were success of therapy [defined as avoidance of secondary interventions (i.e. VATSD or thoracotomy)], chest tube output pre- and post-administration, radiographic findings, t-PA dose and frequency, and bleeding complications.

Results

Thirty-five patients were enrolled: 25 received t-PA and 10 received t-PA + DNase. Successful pharmacologic treatment occurred in 88% of patients receiving t-PA and 100% of patients receiving t-PA + DNase (p = 0.54). In the t-PA group, chest tube output increased from 75 ml/12 h to 538 ml/12 h after administration of t-PA (p = 0.001), and from 103 ml/12 h to 502 ml/12 h (p = 0.001) in the t-PA + DNase group. Radiographic improvement occurred in 84% of t-PA patients and 90% of t-PA + DNase patients (p = 0.99). In the t-PA group, a successful response occurred in 92% of patients receiving a cumulative dose of ≤10 mg (n = 13) and 83% of patients receiving a cumulative dose of >10 mg (n = 12), p = 0.43. Patients who received a single t-PA dose compared to those who received multiple doses also had similar success rates (p = 1). There was one instance of bleeding following drug administration.

Conclusion

Both t-PA and t-PA + DNase were highly effective for reducing a patient's need for surgical intervention. Higher cumulative doses or more frequency administrations did not appear to provide additional benefit.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
复杂胸腔积液胸膜内纤溶治疗及给药策略的评价
目的比较组织纤溶酶原激活剂(t-PA)和t-PA +核糖核酸酶(DNase)在治疗复杂性胸腔积液中的应用,并确定t-PA是否存在剂量-反应关系。方法回顾性队列研究,对一家大型学术医疗中心接受胸膜内t-PA或t-PA + DNase治疗复杂胸腔积液的所有成年患者进行研究。结果是治疗成功[定义为避免二次干预(即VATSD或开胸)],给药前后胸管输出量,x线检查结果,t-PA剂量和频率以及出血并发症。结果纳入35例患者:25例接受t-PA治疗,10例接受t-PA + DNase治疗。t-PA组和t-PA + DNase组的药物治疗成功率分别为88%和100% (p = 0.54)。t-PA组胸管输出量从75 ml/12 h增加到538 ml/12 h (p = 0.001), t-PA + DNase组胸管输出量从103 ml/12 h增加到502 ml/12 h (p = 0.001)。放射学改善发生在84%的t-PA患者和90%的t-PA + DNase患者(p = 0.99)。在t-PA组中,92%接受累计剂量≤10 mg (n = 13)的患者和83%接受累计剂量为>10 mg (n = 12)的患者成功缓解,p = 0.43。与接受多次t-PA剂量的患者相比,接受单次t-PA剂量的患者也有相似的成功率(p = 1)。药物给药后有一例出血。结论t-PA和t-PA + DNase均能有效减少患者手术干预的需要。较高的累积剂量或更频繁的给药似乎没有提供额外的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
41
审稿时长
42 days
期刊介绍: Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews. Research Areas Include: • All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary Toxicology.
期刊最新文献
Elexacaftor/tezacaftor/ivacaftor, a game-changer in cystic fibrosis: The Portuguese experience Editorial Board Lipid nanoparticles for pulmonary fibrosis: A comprehensive review Ensifentrine approval: A milestone in the treatment of COPD FTO promotes gefitinib-resistance by enhancing PELI3 expression and autophagy in non-small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1